27 September 2023
27 September 2023
Although pain affects millions of people worldwide, the industry is still struggling in the ongoing search for safe and effective medication.
Alto Neurosciences has announced the results of its Phase IIa study of its pipeline candidate Alto-100 from the PTSD patient cohort.
The primary outcome of the study is to assess the safety, tolerability and pharmacokinetics of RECCE 327.
The trial will measure DF-006 levels and its compounds in the blood over time following multiple doses of the formulation.
Phase Ia of the trial is expected to be completed in the first half of next year.
The trial will assess NDM670's safety, tolerability and efficacy in ambulatory adult patients with SMA Type III.
Topline clinical data from the trial is expected in the first quarter of next year.
The key objective of the study is to assess the safety, immunogenicity and lot-to-lot consistency of the PIKA Rabies Vaccine.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
